NCT05723692View on ClinicalTrials.gov

A First-In-Human SAD and MAD Study to Evaluate the Safety, Tolerability, PK and PD of SC Administered ALTB-268 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

56

Participants

Timeline

Start Date

January 17, 2023

Primary Completion Date

October 27, 2023

Study Completion Date

October 27, 2023

Conditions

Healthy Volunteers

Interventions

BIOLOGICAL

ALTB-268

monoclonal antibody

OTHER

Placebo

formulation buffer

Trial Locations (1)

66219

ICON Early Development Services, Lenexa

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors

collaborator

ICON plc

INDUSTRY

lead

AltruBio Inc.

INDUSTRY